CompletedPhase 2NCT01813136
Phase II Study of the Optimal Scheme of Administration of Pazopanib in Thyroid Carcinoma
Studying Differentiated thyroid carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Centre Leon Berard
- Principal Investigator
- Christelle De La Fouchardière, MDCentre Léon Bérard, Lyon
- Intervention
- Continuous pazopanib (Arm A)(drug)
- Enrollment
- 168 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2013 – 2019
Study locations (13)
- CHU Angers, Angers, France
- CHU Bordeaux, Bordeaux, France
- Institut Bergonié, Bordeaux, France
- Centre François Baclesse, Caen, France
- CHRU Lille Hôpital Claude Huriez, Lille, France
- Centre Leon Berard, Lyon, France
- Hôpital de la Timone APHM, Marseille, France
- Centre Antoine Lacassagne, Nice, France
- Hôpital Saint-Louis APHP, Paris, France
- Hôpital de la Pitié Salpêtrière APHP, Paris, France
- Institut Jean Godinot, Reims, France
- Institut Claudius Régaud, Toulouse, France
- Institut Gustave Roussy, Villejuif, France
Collaborators
GlaxoSmithKline
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01813136 on ClinicalTrials.govOther trials for Differentiated thyroid carcinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07068542Sacituzumab Tirumotecan Combined With Immunotherapy in Advanced Thyroid CancerZhejiang Provincial People's Hospital
- RECRUITINGPHASE3NCT06860971A Study of AL2846 Capsule Versus Placebo in the Treatment of Advanced Radioiodine-Refractory Differentiated Thyroid CarcinomaChia Tai Tianqing Pharmaceutical Group Co., Ltd.
- RECRUITINGPHASE2NCT06440850Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E MutationCity of Hope Medical Center
- RECRUITINGPHASE2NCT06359847Study of ST-1898 in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid CancerBeijing Scitech-Mq Pharmaceuticals Limited
- RECRUITINGNCT05994365Study of Anlotinib Hydrochloride Capsules in the Treatment of Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid CarcinomaChia Tai Tianqing Pharmaceutical Group Co., Ltd.
- ACTIVE NOT RECRUITINGNANCT06422702The Effect of a Psychosomatic Symptom Intervention Program on the Primary Treatment of Differentiated Thyroid CancerHarbin Medical University
- ACTIVE NOT RECRUITINGNCT04970134Spanish Study for Molecular Characterization of Thyroid CarcinomaGrupo Español de Tratamiento de Tumores de Cabeza y Cuello
- ACTIVE NOT RECRUITINGPHASE2NCT05007093Study on the Treatment of Differentiated Thyroid Carcinoma with AnlotinibYansong Lin